Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder
Purpose of Review
Attention deficit hyperactivity disorder (ADHD) is a widely diagnosed neurodevelopmental disorder giving rise to symptoms of hyperactivity, impulsivity, and inattentiveness that can impair daily functioning. Stimulants, such as methylphenidate and amphetamines, are the mainstay of treatment for ADHD. However, nonstimulant drugs such as viloxazine, atomoxetine, guanfacine, and clonidine are becoming more popular due to minimal adverse effects when compared to stimulants.
Recent Findings
Viloxazine is a selective norepinephrine reuptake inhibitor (NRI) originally used to treat depression in adults with activity in both the noradrenergic as well as serotonergic pathways. Studies have demonstrated its efficacy for its use in the treatment of ADHD. Unlike stimulants, viloxazine has a decreased chance of substance abuse, drug dependance, and withdrawal symptoms upon the cessation of therapy. Additionally, dopamine levels in the nucleus accumbens after treatment with viloxazine are elevated considerably less in comparison with traditional stimulant ADHD treatments. Viloxazine provides an alternative, nonstimulant approach to treating ADHD.
Summary
Viloxazine is a recently approved, non-stimulant medication functions by inhibiting the uptake of norepinephrine which has been seen to be decreased in patients with ADHD. When patients do not respond to first-line stimulants, cannot tolerate the side effects, or have contraindications to stimulants, viloxazine may be a nonstimulant option offering patients an increasing arsenal of medications to treat ADHD.
1. Faraone SV, Asherson P, Banaschewski T, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2015;1. doi:10.1038/nrdp.2015.20
2. Luo Y, Weibman D, Halperin JM, Li X. A review of heterogeneity in attention deficit/hyperactivity disorder(ADHD). Front Hum Neurosci. 2019;13. doi:10.3389/fnhum.2019.00042
3. Posner J, Polanczyk GV, Soruga-Barke E. Attention-deficit hyperactivity disorder. The Lancet. 2020;395(10222):450-462. doi:10.1016/s0140-6736(19)33004-1
4. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. doi:10.1176/ajp.2006.163.4.716
5. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4). doi:10.1542/peds.2019-2528
6. Kasparek T, Theiner P, Filova A. Neurobiology of ADHD From Childhood to Adulthood: Findings of Imaging Methods. J Atten Disord. 2015;19(11):931-943. doi:10.1177/1087054713505322
7. Barkley RA, Fischer M, Smallish L, Fletcher K. Young Adult Outcome of Hyperactive Children: Adaptive Functioning in Major Life Activities. Journal of the American Academy of Child & Adolescent Psychiatry. 2006;45(2):192-202. doi:10.1097/01.chi.0000189134.97436.e2
8. Excellence NI for H and C. Attention deficit hyperactivity disorder: Diagnosis and management. NICE guideline [NG87]. https://www.nice.org.uk/guidance/NG87
9. Network SIG. Management of attention deficit and hyperkinetic disorders in children and young people. http://www.sign.ac.uk/guidelines/fulltext/112/index.html
10. Chan E, Fogler JM, Hammerness PG. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. JAMA. 2016;315(18):1997-2008. doi:10.1001/jama.2016.5453
11. Feldman ME, Charach A, Bélanger SA. ADHD in children and youth: Part 2-Treatment. Paediatr Child Health. 2018;23(7):462-472. doi:10.1093/pch/pxy113
12. Harpin VA. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006. Arch Dis Child Educ Pract Ed. 2008;93(2):58-65. doi:10.1136/adc.2006.106864
13. Pliszka S, Issues AWG on Q. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921. doi:10.1097/chi.0b013e318054e724
14. Taylor EE. European clinical guidelines for hyperkinetic disorder-- first upgrade. European Child & Adolescent Psychiatry. 2004;13(S1):7-30. doi:10.1007/s00787-004-1002-x
15. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4). doi:10.1542/peds.2019-2528
16. Antshel KM, Hargrave TM, Simonescu M, Kaul P, Hendricks K, Faraone SV. Advances in understanding and treating ADHD. BMC Med. 2011;9:72. doi:10.1186/1741-7015-9-72
17. Sibley MH, Kuriyan AB, Evans SW, Waxmonsky JG, Smith BH. Pharmacological and psychosocial treatments for adolescents with ADHD: an updated systematic review of the literature. Clin Psychol Rev. 2014;34(3):218-232. doi:10.1016/j.cpr.2014.02.001
18. Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020;395(10222):450-462. doi:10.1016/s0140-6736(19)33004-1
19. Luo Y, Weibman D, Halperin JM, Li X. A Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder(ADHD). Front Hum Neurosci. 2019;13:42. doi:10.3389/fnhum.2019.00042
20. Strohl MP. Bradley's Benzedrine studies on children with behavioral disorders. Yale J Biol Med. 2011;84(1):27-33. https://www.ncbi.nlm.nih.gov/pubmed/21451781
21. Pelham WE Jr, Fabiano GA, Waxmonsky JG, et al. Treatment Sequencing for Childhood ADHD: A Multiple-Randomization Study of Adaptive Medication and Behavioral Interventions. J Clin Child Adolesc Psychol. 2016;45(4):396-415. doi:10.1080/15374416.2015.1105138
22. Chacko A, Bedard ACV, Marks D, et al. Sequenced neurocognitive and behavioral parent training for the treatment of ADHD in school-age children. Child Neuropsychol. 2018;24(4):427-450. doi:10.1080/09297049.2017.1282450
23. Drugs for ADHD. Med Lett Drugs Ther. 2015;57(1464):37-40. https://www.ncbi.nlm.nih.gov/pubmed/25758544
24. Wender EH. Managing stimulant medication for attention-deficit/hyperactivity disorder. Pediatr Rev. 2001;22(6):183-190. doi:10.1542/pir.22-6-183
25. Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents- UpToDate. Accessed June 27, 2022. http s://www.uptodate.com/contents/pharmacology-of-dr ugs-used-to-treat-attention-deficit-hyperactivity-disorder-in-children-and-adolescents
26. Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry. 2009;48(3):240-248. doi:10.1097/chi.0b013e318197748f
27. Clavenna A, Bonati M. Safety of medicines used for ADHD in children: a review of published prospective clinical trials. Arch Dis Child. 2014;99(9):866-872. doi:10.1136/archdischild-2013-304170
28. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1284-1293. doi:10.1097/01.chi.0000235077.32661.61
29. Coghill DR, Banaschewski T, Nagy P, et al. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV,2-Year, Open-Label Study in Europe. CNS Drugs. 2017;31(7):625-638. doi:10.1007/s40263-017-0443-y
30. Punja S, Shamseer L, Hartling L, et al. Amphetamines for attention deficit hyperactivity disorder(ADHD) in children and adolescents. Cochrane Database Syst Rev. 2016;2:CD009996. doi:10.1002/14651858.cd009996.pub2
31. Kidwell KM, van Dyk TR, Lundahl A, Nelson TD. Stimulant Medications and Sleep for Youth With ADHD: A Meta-analysis. Pediatrics. 2015;136(6):1144-1153. doi:10.1542/peds.2015-1708
32. Storebo OJ, Pedersen N, Ramstad E, et al. Methylphenidate for attention deficit hyperactivity disorder(ADHD) in children and adolescents-assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev. 2018;5:CD012069. doi:10.1002/14651858.cd012069.pub2
33. Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am. 2011;58(1):99-120, xi. doi:10.1016/j.pcl.2010.10.009
34. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45(4):408-414. doi:10.1097/01.chi.0000199027.68828.b3
35. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. JAm Acad Child Adolesc Psychiatry. 2008;47(1):21-31. doi:10.1097/ch i.0b013e31815a56f1
36. Yu G, Li GF, Markowitz JS. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. J Child Adolesc Psychopharmacol. 2016;26(4):314-326. doi:10.1089/cap.2015.0137
37. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90(suppl_1):i26-i29. doi:10.1136/adc.2004.059386
38. Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety. I Psychopharmacol. 2014;28(3):204-211. doi:10.1177/0269881113478475
39. Schonwald A. Update: attention deficit/hyperactivity disorder in the primary care office. Curr Opin Pediatr. 2005;17(2):265-274. doi:10.1097/01.mop.0000156983.71532.eb
40. Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53(2):174-187. doi:10.1016/j.jaac.2013.11.005
41. Reed VA, Buitelaar JK, Anand E, et al. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research. CNS Drugs. 2016;30(7):603-628. doi:10.1007/s40263-016-0349-0
42. Donnelly C, Bangs M, Trzepacz P, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. JAm Acad Child Adolesc Psychiatry. 2009;48(2):176-185. doi:10.1097/c hi.0b013e318193060e
43. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. JAm Acad Child Adolesc Psychiatry. 2008;47(2):209-218. doi:10.1097/c hi.0b013e31815d88b2
44. Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf. 2008;31(4):345-354. doi:10.2165/00002018-200831040-00008
45. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. JAm Acad Child Adolesc Psychiatry. 2007;46(2):242-251. doi:10.1097/01.chi.0000246056.83791.b6
46. Stojanovski SD, Casavant MJ, Mousa HM, Baker P, Nahata MC. Atomoxetine-induced hepatitis in a child. Clin Toxicol(Phila). 2007;45(1):51-55. doi:10.1080/15563650600795644
47. Lim JR, Faught PR, Chalasani NP, Molleston JP. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr. 2006;148(6):831-834. doi:10.1016/j.jpeds.2006.01.035
48. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;38(12):1551-1559. doi:10.1097/00004583-199912000-00017
49. Palumbo DR, Sallee FR, Pelham WE Jr, Bukstein OG, Daviss WB, McDermott MP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(2):180-188. doi:10.1097/chi.0b013e31815d9af7
50. Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127(6):e1406-e1413. doi:10.1542/peds.2010-1260
51. Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. JAm Acad Child Adolesc Psychiatry. 2009;48(9):884-893. doi:10.1097/chi.0b013e3181b26e9f
52. Tourette's Syndrome Study G. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58(4):527-536. doi:10.1212/wn 1.58.4.527
53. Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder(ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018;2018(6):CD007990. doi:10.1002/14651858.cd007990.pub3
54. Newcorn JH, Harpin V, Huss M, et al. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatr. 2016;57(6):717-728. doi:10.1111/jcpp.12492
55. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155-165. doi:10.1097/chi.0b013e318191769e
56. Cutler AJ, Brams M, Bukstein O, et al. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. JAm Acad Child Adolesc Psychiatry. 2014;53(10):1092-1101. doi:10.1016/j.jaac.2014.08.001
57. Wilens TE, Robertson B, Sikirica V, et al. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(11):916-925.e2. doi:10.1016/j.jaac.2015.08.016
58. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74-85.e2. doi:10.1016/j.jaac.2011.10.012
59. Otasowie J, Castells X, Ehimare UP, Smith CH. Tricyclic antidepressants for attention deficit hyperactivity disorder(ADHD) in children and adolescents. Cochrane Database Syst Rev. 2014;(9):CD006997. doi:10.1002/14651858.cd006997.pub2
60. Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R. Treatment of attention-deficit/hyperactivity disorder. Evid Rep Technol Assess(Summ). 1999;11:1-341, i-viii. https://www.ncbi.nlm.nih.gov/pubmed/10790990
61. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996;35(10):1314-1321. doi:10.1097/00004583-199610000-00018
62. Biederman J, Spencer T. Non-stimulant treatments for ADHD. Eur Child Adolesc Psychiatry. 2000;9(S1):S51-S59. doi:10.1007/s007870070019
63. Lamb YN. Viloxazine: Pediatric First Approval. Pediatr Drugs. 2021;23(4):403-409. doi:10.1007/s40272-021-00453-3
64. Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020;12:285-300. doi:10.2147/jep.s256586
65. Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of Coadministered Viloxazine Extended-Release(SPN-812) and Lisdexamfetamine in Healthy Adults. J Clin Psychopharmacol. 2021;41(2):155-162. doi:10.1097/jcp.0000000000001361
66. Pozzi M, Bertella S, Gatti E, et al. Emerging drugs for the treatment of attention-deficit hyperactivity disorder(ADHD). Expert Opin Emerg Drugs. 2020;25(4):395-407. doi:10.1080/14728214.2020.1820481
67. Cutler AJ, Mattingly GW, Jain R, O'Neal W. Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. CNS Spectr. 2022;27(2):199-207. doi:10.1017/s1092852920001984
68. Supernus Pharmaceuticals Inc. Supernus Announces Issuance of First Use Patents Protecting SPN-812 as a Novel Non-Stimulant ADHD Product. Media A, ed. https://ir.supernus.com/news-releases/news-release-details/supernus-announces-issuance-first-use-patents-protecting-spn-812
69. Medicine NIHNL of. QELBREE-viloxazine hydrochloride capsule, extended release Drug Label Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aedf408d-0f84-418d-9416-7c39ddb0d29a
70. Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of violaazine: Serotonin and norepinephrine modulating properties. Journal of Experimental Pharmacology. 2020;12:285-300. doi:10.2147/jep.s256586
71. Viloxazine: Drug information- UpToDate. Accessed June 6, 2022. https://www.uptodate.com/contents/viloxazine-drug-information?search=viloxazine&source=panel_search_result&selectedTitle=1~3&usage_type=panel&kp_tab=drug_general&display_rank=1#F55756520
72. Lamb YN. Viloxazine: Pediatric First Approval. Pediatr Drugs. 2021;23(4):403-409. doi:10.1007/s40272-021-00453-3
73. Findling RL, Candler SA, Nasser AF, et al. Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs. 2021;35(6):643-653. doi:10.1007/s40263-021-00825-W
74. Dostert P, Benedetti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor[discussion S71-3]. Eur Neuropsychopharmacol. 1997;7(1):S23-S35. doi:10.1016/s0924-977x(97)00417-3
75. Yamaguchi H, Nagumo K, Nakashima T, Kinugawa Y, Kumaki S. Life-threatening QT prolongation in a boy with attention-deficit/hyperactivity disorder on atomoxetine. European Journal of Pediatrics. 2014;173(12):1631-1634. doi:10.1007/S00431-013-2206-1/FIGURES/3
76. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Safety. 2003;26(10):729-740. doi:10.2165/00002018-200326100-00006/FIGURES/TAB5
77. Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. Journal of Experimental Pharmacology. 2020;12:285-300. doi:10.2147/jep.s256586
78. Mehta TR, Monegro A, Nene Y, Fayyaz M, Bollu PC. Neurobiology of ADHD: A Review. Current Developmental Disorders Reports. 2019;6(4):235-240. doi:10.1007/S40474-019-00182-W/FIGURES/1
79. Zhang S, Faries DE, Vowles M, Michelson D. ADHD rating scale IV: psychometric properties from a multinational study as clinician-administered instrument. Int J Methods Psychiatr Res. 2005;14(4):186-201. doi:10.1002/mpr.7
80. Johnson JK, Liranso T, Saylor K, et al. A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812(Extended-Release Viloxazine) in Children With ADHD. JAtten Disord. 2020;24(2):348-358. doi:10.1177/1087054719836159
81. Kennett GA, Trail B, Bright F. Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated. Neuropharmacology. 1998;37(12):1603-1610. doi:10.1016/s0028-3908(98)00115-4
82. Kennett GA, Wood MD, Bright F, et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997;36(4-5):609-620. doi:10.1016/s0028-3908(97)00038-5
83. Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology(Berl). 2005;177(4):448-458. doi:10.1007/s00213-004-1962-z
84. Cornish JL, Kalivas PW. Glutamate Transmission in the Nucleus Accumbens Mediates Relapse in Cocaine Addiction. J Neurosci. 2000;20(15):RC89-RC89. doi:10.1523/jneurosci.20-15-j0006.2000
85. di Chiara G, Bassareo V, Fenu S, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology. 2004;47(SUPPL.1):227-241. doi:10.1016/j.neuropharm.2004.06.032
86. Covey DP, Bunner KD, Schuweiler DR, Cheer JF, Garris PA. Amphetamine elevates nucleus accumbens dopamine via an action potential-dependent mechanism that is modulated by endocannabinoids. Eur J Neurosci. 2016;43(12):1661-1673. doi:10.1111/ejn.13248
87. Wilens TE. Impact of ADHD and Its Treatment on Substance Abuse in Adults. J Clin Psychiatry. 2004;65(3).
88. Kalbag AS, Levin FR. Adult ADHD and Substance Abuse: Diagnostic and Treatment Issues. Substance Use & Misuse. 2005;40(13-14):1955-1981. doi:10.1080/10826080500294858
89. Yu C. Metabolism and in vitro drug-drug interaction assessment of viloxazine. Xenobiotica. 2020;50(11):1285-1300. doi:10.1080/00498254.2020.1767319
90. Pisani F, Fazio A, Spina E, et al. Pharmacokinetics of the antidepressant drug violaazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. Psychopharmacology. 1986;90(3):295-298. doi:10.1007/bf00179180
91. Vandel B, Vandel S, Jounet JM, Blum D. Pharmacokinetics of viloxazine hydrochloride in man. European Journal of Drug Metabolism and Pharmacokinetics. 1982;7(1):65-68. doi:10.1007/bf03189545
92. Nasser A, Gomeni R, Wang Z, et al. Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder. The Journal of Clinical Pharmacology. 2021;61(12):1626-1637. doi:10.1002/jcph.1940
93. Ibrahim K, Vogt C, Donyai P. Caught in the eye of the storm: a qualitative study of views and experiences of planned drug holidays from methylphenidate in child and adolescent ADHD treatment. Child Adolesc Ment Health. 2016;21(4):192-200. doi:10.1111/camh.12156
94. Shyu YC, Lee SY, Yuan SS, et al. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine. Clin Ther. 2016;38(3):595-602. doi:10.1016/j.clinthera.2016.01.015
95. Desai M, Oppenheimer JJ. Medication Adherence in the Asthmatic Child and Adolescent. Curr Allergy Asthma Rep. 2011;11(6):454-464. doi:10.1007/s11882-011-0227-2
96. Taddeo D, Egedy M, Frappier JY. Adherence to treatment in adolescents. Paediatrics & Child Health. 2008;13(1):19-24. doi:10.1093/pch/13.1.19
97. Nasser A, Liranso T, Adewole T, et al. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812(Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children. Clinical Therapeutics. 2020;42(8):1452-1466. doi:10.1016/j.clinthera.2020.05.021
98. Nasser A, Liranso T, Adewole T, et al. Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial. Clinical Therapeutics. 2021;43(4):684-700. doi:10.1016/j.clinthera.2021.01.027
99. Johnson JK, Liranso T, Saylor K, et al. A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812(Extended-Release Viloxazine) in Children With ADHD. J Atten Disord. 2020;24(2):348-358. doi:10.1177/1087054719836159
100. Nasser A, Liranso T, Adewole T, et al. A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder. J Clin Psychopharmacol. 2021;41(4):370-380. doi:10.1097/jcp.0000000000001404
101. Nasser A, Liranso T, Adewole T, et al. A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812(Viloxazine Extended-Release) in Adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43-64.
102. Nasser A, Faison SL, Liranso T, et al. Evaluation of the Effect of SPN-812(Viloxazine Extended-Release) on QTc Interval in Healthy Adults. J Clin Psychiatry. 2020;81(6). doi:10.4088/jcp.20m13395
103. Edinoff AN, Akuly HA, Wagner JH, et al. Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder. Front Psychiatry. 2021;12:789982. doi:10.3389/fpsyt.2021.789982
104. Banaschewski T, Becker K, Dopfner M, Holtmann M, Rosler M, Romanos M. Attention-Deficit/Hyperactivity Disorder. Deutsches Arzteblatt international. 2017;114(9):149-159. doi:10.3238/arztebl.2017.0149
105. Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of Coadministered Viloxazine Extended-Release(SPN-812) and Methylphenidate in Healthy Adults. Clin Drug Investig. 2021;41(2):149-159. doi:10.1007/s40261-020-00992-6
106. Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of Coadministered Viloxazine Extended-Release(SPN-812) and Lisdexamfetamine in Healthy Adults. J Clin Psychopharmacol. 2021;41(2):155-162. doi:10.1097/jcp.0000000000001361
107. Edinoff AN, Akuly HA, Wagner JH, et al. Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder. Front Psychiatry. 2021;12:789982. doi:10.3389/fpsyt.2021.789982